SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (196)9/15/1997 9:18:00 PM
From: JOSEPH VON MEISTER   of 1826
 
I think the confusion in dosing comes from MGI's use of mg/m^2 for humans and mg/kg for mice. The company line was that a surface area dosing was more accurate than a weight based dosing. I think that this was a smoke screen to confuse any comparisons with the published animal tests. I specualte that the reason for this was that 114, when tested on dogs, caused toxicity at 8-9 mg/m^2.

So they were expecting the posibility of toxicity at lower dose rates based on the tests on canines. Human's seem to be more like rats than dogs in their ability to tolerate the drug, however. As of the last conference call the dose rate was 14 mg/m^2. I expect they will dose escalate again this month, with the MTD to be reached by year end in the low 20's. The dose is escalated by roughly 1/3 each round.

JVM
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News